OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hong on the Efficiency of the CodeBreaK 101 Trial in KRAS G12C-Mutated CRC and Other Solid Tumors

January 22nd 2022

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.

Dr. Bekaii-Saab on the Updated Results of the KRYSTAL-1 Trial in KRAS G12C+ GI Cancers

January 22nd 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

Dr. LeBeau on the Potential Utility of Shark VNAR Proteins in Prostate Cancer

January 21st 2022

Aaron LeBeau, PhD, discusses the potential of shark variable domain of new antigen receptor proteins in prostate cancer.

Dr. Abrams on the Rationale for the COSMIC-021 Trial in MSS/pMMR CRC

January 21st 2022

Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer.

Dr. Raghav on the Rationale for the DESTINY-CRC02 Trial in HER2+ mCRC

January 21st 2022

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer.

Dr. Mesa on Future Research Efforts With JAK Inhibitors in Myelofibrosis

January 21st 2022

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.

Dr. Simon on Ensuring Health Equity in Cancer Care

January 21st 2022

Melissa A. Simon, MD, discusses ensuring health equity in cancer care.

Dr. Mitchell on ECOG-ACRIN’s Efforts in Addressing Health Disparities in Cancer Care

January 21st 2022

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.

Dr. Azzi on the Unmet Needs the Signatera ctDNA Assay Could Fulfill in CRC

January 20th 2022

Georges Azzi, MD, discusses the unmet needs the Signatera circulating tumor DNA assay could fulfill in colorectal cancer.

Dr. Lenz on the Rationale for the CheckMate 9X8 Trial in Metastatic CRC

January 20th 2022

Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Dr. Kopetz on the Rationale for the BREAKWATER Trial in BRAF V600E-Mutant mCRC

January 20th 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.

Dr. Chandra on Assessing Mitochondrial Function to Inform Outcomes in Prostate Cancer

January 19th 2022

Dhyan Chandra, PhD, discusses the potential to assess mitochondrial function to inform outcomes in prostate cancer.

Dr. Harrison on Unmet Needs in Myelofibrosis

January 19th 2022

Claire Harrison, MD, FRCP, FRCPath, discusses current unmet needs in myelofibrosis.

Dr. Woloszynska on the Need to Assess Biological Factors of Racial Disparities in Prostate Cancer

January 19th 2022

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.

Dr. Bakouny on Understanding the Biology of Translocation RCC

January 19th 2022

Ziad Bakouny, MD, MSc, discusses understanding the biology of translocation renal cell carcinoma.

Dr. Cole on Next Steps With Tucatinib in HER2+ Breast Cancer

January 19th 2022

John Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.

Dr. Phillips Discusses Ongoing Research With BTK Inhibitors in MCL

January 19th 2022

Tycel Jovelle Phillips, MD, discusses ongoing research with BTK inhibitors in mantle cell lymphoma.

Dr. Perez on the Potential Utility of KIN-2787 in BRAF-Mutated Solid Tumors

January 19th 2022

Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.

Dr. Yentz on Translating Data to Real-World Clinical Practice in RCC

January 18th 2022

Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.

Dr. McKinney on the Potential for Curative-Intent Therapies in MCL

January 18th 2022

Matthew S. McKinney, MD, discusses the potential for curative-intent therapies in mantle cell lymphoma.